SciBase Completes Successful Directed Share Issue Raising SEK 11 Million
On June 30, 2025, SciBase Holding AB (publ), a notable player in the medical technology field, officially announced the results of its directed share issue. This decision was made following the authorization from the annual general meeting convened on June 17, 2025. The company had announced a substantial capital raise of approximately SEK 11 million through this new issue, which took place with a deviation from the usual preferential rights of existing shareholders.
The directed share issue was subscription priced at SEK 0.40 per share, demonstrating the company’s strategic initiative to secure funds necessary for its operational and developmental projects. Notably, the issue was taken up entirely, with shares allotted to three significant investors: Haga Gruppen Holding AB, Life Science Invest Fund 1 ApS, and Ribbskottet AB.
The impact of this capital acquisition is significant; the new share issuance will enhance SciBase's share capital by SEK 1.4 million, with the issuance of a total of 28 million new shares. However, this move translates to a dilution of approximately 7.6% for the existing shareholders, which is critical information for those currently holding company stock.
SciBase's management team has expressed optimism about this influx of capital, which they intend to use for advancing their key products and research initiatives, particularly the Nevisense system. Nevisense is a pioneering platform that employs artificial intelligence alongside advanced electrical impedance spectroscopy (EIS) technology for diagnosing skin conditions early. This reinforces the company's overarching commitment to reducing patient suffering and improving healthcare outcomes through technological advancements.
The company's roots lie in over two decades of research at the esteemed Karolinska Institutet in Stockholm, highlighting its dedication to innovation in dermatology. Since July 2015, SciBase has been listed on the Nasdaq First North Growth Market, marking its presence in the stock market and assuring shareholders of continuous growth.
This funding is expected to not only assist in expanding their market presence but also to bolster their research capabilities in developing next-generation medical technology. As such, it will be essential for success in a fiercely competitive market, where early detection technology can significantly lower long-term healthcare costs and outcomes for patients.
Moreover, investors should be aware of the importance of regulations governing investments within certain jurisdictions. The communication concerning this share issue expressly states that the content should not be shared in several specified locations including, but not limited to, Australia, Canada, Japan, and the United States among others. Therefore, individuals in these regions need to be cautious about the implications of the share offering.
Going forward, investors and stakeholders are encouraged to remain informed about future endeavors and legislative matters affecting SciBase, as the company continues to focus on delivering innovative solutions for medical diagnostics. For those seeking to keep abreast of developments, regular updates are available through the company's investor relations portal, which will highlight forthcoming products, financial releases, and other significant company news.
In conclusion, SciBase's recent directed share issue signifies a strategic move to secure essential funds while navigating the complex landscape of investor relations and regulatory challenges. As the company prepares for substantial developments ahead, both the industry and shareholders will be watching closely. Those who have invested in SciBase can expect further communication regarding the impact of this raise and the company's direction as it continues to lead in dermatology innovation.
The directed share issue was subscription priced at SEK 0.40 per share, demonstrating the company’s strategic initiative to secure funds necessary for its operational and developmental projects. Notably, the issue was taken up entirely, with shares allotted to three significant investors: Haga Gruppen Holding AB, Life Science Invest Fund 1 ApS, and Ribbskottet AB.
The impact of this capital acquisition is significant; the new share issuance will enhance SciBase's share capital by SEK 1.4 million, with the issuance of a total of 28 million new shares. However, this move translates to a dilution of approximately 7.6% for the existing shareholders, which is critical information for those currently holding company stock.
SciBase's management team has expressed optimism about this influx of capital, which they intend to use for advancing their key products and research initiatives, particularly the Nevisense system. Nevisense is a pioneering platform that employs artificial intelligence alongside advanced electrical impedance spectroscopy (EIS) technology for diagnosing skin conditions early. This reinforces the company's overarching commitment to reducing patient suffering and improving healthcare outcomes through technological advancements.
The company's roots lie in over two decades of research at the esteemed Karolinska Institutet in Stockholm, highlighting its dedication to innovation in dermatology. Since July 2015, SciBase has been listed on the Nasdaq First North Growth Market, marking its presence in the stock market and assuring shareholders of continuous growth.
This funding is expected to not only assist in expanding their market presence but also to bolster their research capabilities in developing next-generation medical technology. As such, it will be essential for success in a fiercely competitive market, where early detection technology can significantly lower long-term healthcare costs and outcomes for patients.
Moreover, investors should be aware of the importance of regulations governing investments within certain jurisdictions. The communication concerning this share issue expressly states that the content should not be shared in several specified locations including, but not limited to, Australia, Canada, Japan, and the United States among others. Therefore, individuals in these regions need to be cautious about the implications of the share offering.
Going forward, investors and stakeholders are encouraged to remain informed about future endeavors and legislative matters affecting SciBase, as the company continues to focus on delivering innovative solutions for medical diagnostics. For those seeking to keep abreast of developments, regular updates are available through the company's investor relations portal, which will highlight forthcoming products, financial releases, and other significant company news.
In conclusion, SciBase's recent directed share issue signifies a strategic move to secure essential funds while navigating the complex landscape of investor relations and regulatory challenges. As the company prepares for substantial developments ahead, both the industry and shareholders will be watching closely. Those who have invested in SciBase can expect further communication regarding the impact of this raise and the company's direction as it continues to lead in dermatology innovation.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.